Knight Therapeutics Inc. (GUD.TO) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-26). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from published company financials, balance sheet as of 2025-12-31. GUD.TO files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 7.99% | 30.00% | Pass |
| Interest-bearing investments | 9.78% | 30.00% | Pass |
| Non-permissible income | 1.38% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 8.40% | 33.00% | Pass |
| Interest-bearing investments | 9.12% | 33.00% | Pass |
| Non-liquid assets | 78.67% | at least 20.00% | Pass |
| Non-permissible income | 1.38% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 7.45% | 33.33% | Pass |
| Cash + interest-bearing securities | 9.12% | 33.33% | Pass |
| Accounts receivable | 21.33% | 33.33% | Pass |
| Non-permissible income | 1.38% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 7.45% | 33.33% | Pass |
| Cash + interest-bearing securities | 9.12% | 33.33% | Pass |
| Accounts receivable | 21.33% | 50.00% | Pass |
| Non-permissible income | 1.38% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.75% | 33.00% | Pass |
| Cash + interest-bearing securities | 14.38% | 33.00% | Pass |
| Accounts receivable | 19.27% | 33.00% | Pass |
| Non-permissible income | 1.38% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.34% | 33.00% | Pass |
| Cash + interest-bearing securities | 15.11% | 49.00% | Pass |
| Accounts receivable | 20.24% | 49.00% | Pass |
| Non-permissible income | 1.38% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.34% | 33.33% | Pass |
| Cash + interest-bearing securities | 15.11% | 33.33% | Pass |
| Accounts receivable | 35.35% | 49.00% | Pass |
| Non-permissible income | 1.38% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 50.80 | NEUTRAL |
| Stochastic %K (14) | 51.95 | NEUTRAL |
| CCI (20) | 42.56 | NEUTRAL |
| Williams %R (14) | -48.05 | NEUTRAL |
| MACD (12,26,9) | 0.02 | BUY |
| ROC (10) | -0.31 | SELL |
| Momentum (10) | -0.03 | SELL |
| EMA (10) | 9.79 | SELL |
| SMA (10) | 9.76 | SELL |
| EMA (20) | 9.73 | SELL |
| SMA (20) | 9.70 | BUY |
| EMA (30) | 9.69 | BUY |
| SMA (30) | 9.65 | BUY |
| EMA (50) | 9.55 | BUY |
| SMA (50) | 9.72 | BUY |
| EMA (100) | 9.03 | BUY |
| SMA (100) | 9.09 | BUY |
| EMA (200) | 7.94 | BUY |
| SMA (200) | 7.70 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.